Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not yet recruiting

Study on the Effect of Povidone-Iodine, Hydrogen Peroxide, and Water for Injection on COVID-19, Influenza A, and RSV in Patients

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of different oral antiseptics on certain respiratory viruses, specifically in patients diagnosed with COVID-19, influenza A, or respiratory syncytial virus (RSV). The trial will use antiseptics such as Betadine bucal, which contains the active ingredient povidone-iodine, and Agua oxigenada Foret, which contains hydrogen peroxide. These antiseptics are used as mouth rinses to see how effectively they can reduce the presence of these viruses in saliva.

The purpose of the study is to analyze the immediate effect of these antiseptics on the viral load in saliva and to determine how long this effect lasts, up to 7 hours after a single rinse. Participants will use the mouthwash, and samples of their saliva will be collected at different times to measure the amount of virus present. This will help researchers understand the potential of these antiseptics in reducing the spread of respiratory viruses.

The study will involve participants who have been diagnosed with one of the mentioned respiratory viruses and have shown symptoms for less than 5 days. The trial will not include those who are currently receiving antiviral treatments. The findings from this study could provide valuable insights into the use of oral antiseptics as a simple method to help control the spread of respiratory infections.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the clinical trial, an initial assessment is conducted to confirm eligibility. This includes verifying a diagnosis of infection by respiratory viruses such as COVID-19, influenza A, or RSV. It is important that less than 5 days have passed since the appearance of symptoms and that no antiviral treatment is being received. Participants must be over 16 years old.

  2. Step 2

    First mouthwash application

    The first step in the trial involves using a mouthwash solution. The solution contains povidone, iodinated, hydrogen peroxide, and water for injection. The mouthwash is used by rinsing the mouth thoroughly, which is referred to as buccal use.

  3. Step 3

    Sample collection

    After the mouthwash application, a saliva sample is collected. This sample is used to measure the viral load, which indicates the amount of virus present in the saliva.

  4. Step 4

    Monitoring period

    The effect of the mouthwash is monitored for up to 7 hours. During this time, additional saliva samples may be collected to assess the duration of the mouthwash's effect on reducing the viral load.

  5. Step 5

    Data analysis

    The collected samples are analyzed to determine the D/T ratio, which helps quantify the proportion of intact viral particles. This analysis provides insight into the effectiveness of the mouthwash in reducing the presence of the virus.

Who can join the trial?

4 criteria

  • Have a diagnosis of infection by one of the following respiratory viruses: COVID-19, influenza A, or RSV (Respiratory Syncytial Virus).
  • Have had symptoms for less than 5 days. Symptoms are the signs of illness you can feel or see.
  • Not be receiving any type of antiviral treatment. Antiviral treatment is medicine used to treat viral infections.
  • Be over 16 years old.

Who cannot join the trial?

5 criteria

  • Patients who do not have a diagnosis of COVID-19, influenza A, or RSV (Respiratory Syncytial Virus) cannot participate.
  • Patients who are not within the specified age range for the study cannot participate.
  • Patients who are not able to provide informed consent cannot participate.
  • Patients with any condition that the study doctors believe would make it unsafe for them to participate cannot join the study.
  • Patients who are currently participating in another clinical trial cannot participate.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not yet recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Oral Antiseptic 1

    is a mouthwash used in this trial to help reduce the amount of viruses in the mouth. When you rinse your mouth with this antiseptic, it can kill or inactivate viruses like COVID-19, influenza A, and RSV. The goal is to see how well it works right after you use it and how long the effect lasts, up to 7 hours.

  • Oral Antiseptic 2

    is another type of mouthwash being tested in the trial. Similar to the first antiseptic, it is designed to target and reduce viruses in your saliva. By using this rinse, the study aims to understand its immediate effect on viruses and how long it can keep the virus levels low in your mouth.

  • Oral Antiseptic 3

    is also part of the trial and works like the other antiseptics. It is used to rinse the mouth and is tested for its ability to kill or reduce the presence of viruses in the saliva. The trial examines how quickly it acts against the viruses and the duration of its effectiveness over several hours.

What is already known about the treatment

Oral Antiseptics – These medications are administered as a mouth rinse and are used to reduce the presence of viruses in the mouth. They are currently being studied for their ability to kill viruses like COVID-19, influenza A, and RSV in saliva. The main use of these antiseptics is to help manage respiratory diseases by reducing viral load in the mouth. They work by disrupting the outer layer of the virus, which prevents it from functioning properly. These antiseptics are classified as antimicrobial agents and are being evaluated for their effectiveness in providing immediate and lasting effects up to 7 hours after use.

Investigated diseases

  • COVID-19

    COVID-19 is a respiratory illness caused by the coronavirus SARS-CoV-2. It primarily affects the respiratory system, leading to symptoms such as fever, cough, and difficulty breathing. The virus spreads through respiratory droplets and can lead to inflammation in the lungs. As the disease progresses, it may cause pneumonia and acute respiratory distress syndrome. In some cases, it can affect other organs, leading to a wide range of symptoms. The progression and severity of the disease can vary significantly among individuals.

  • Influenza A

    Influenza A is a viral infection that affects the respiratory system, caused by the influenza A virus. It is characterized by symptoms such as fever, cough, sore throat, and muscle aches. The virus spreads through respiratory droplets and can lead to inflammation of the airways. As the infection progresses, it may cause complications like pneumonia, especially in vulnerable populations. The virus can undergo frequent genetic changes, leading to seasonal outbreaks. The severity of symptoms can vary, with some individuals experiencing mild illness and others more severe respiratory issues.

  • Respiratory Syncytial Virus (RSV) Infection

    Respiratory Syncytial Virus (RSV) infection is a common respiratory virus that primarily affects the lungs and airways. It is most prevalent in infants and young children, causing symptoms such as runny nose, cough, and wheezing. The virus spreads through respiratory droplets and can lead to bronchiolitis or pneumonia. As the infection progresses, it may cause increased difficulty in breathing and decreased oxygen levels. RSV can also affect older adults and individuals with weakened immune systems. The severity of the infection can range from mild cold-like symptoms to more serious respiratory conditions.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-515939-30-01Protocol codeOralAntiseptic_VirusEstimated enrolment810 patientsSponsorFundacion Publica Galega Instituto De Investigacion Sanitaria De Santiago De Compostela

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).